Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

DaT-uptake z-scores for Caudate and Striatum Predict Levodopa Requirement in Early Parkinson’s Disease
Movement Disorders
S37 - Movement Disorders: Phenotyping and Biomarkers (2:36 PM-2:48 PM)
009
Personalised medicine driven by clinical biomarkers is the state-of-art management approach for PD. Whether pattern of striatal dopaminergic deficiency (demonstrated by single-photon emission CT (SPECT) scanning with 123I-Ioflupane, DaTSCAN) could serve as a biomarker predicting levodopa requirement in early PD is not known.
We explored whether striatal dopaminergic availability may predict Levodopa Equivalent Daily Dose (LEDD) requirements in People with early Parkinson’s disease (PD, PwP).

Participants with early PD (disease duration (DD) ≤5 years, Hoehn and Yahr (HY) ≤3) who underwent DaTSCAN as a part of a clinical-diagnostic work up were enrolled in the “Non-motor Longitudinal International Study” (UK National Institute for Health Research Clinical Research Network Number 10084) and were included in this cross-sectional analysis. Specific DaTSCAN binding ratios were analyzed for each striatum, caudate and putamen and the z-scores were derived normalizing the images to age and gender-matched healthy controls from the European-Database-of-DaTSCAN-of-healthy-controls (ENC-DAT). The normality of data distribution was tested (One-sample Kolmogorov– Smirnov test) and descriptive statistics provided. Using linear regression analysis, we explored the impact of DaT-uptake z-scores for more severely affected putamen, caudate and striatum on the LEDD. Statistically significant predictors identified in the univariable analysis were included in the multivariable analysis with DD and HY as additional independent variables. (SPSS, Version 28).  

43 PwP (30.2 %female; age: 61.91±11.45years; DD: 2(0-5)years; HY: 2(1-3); LEDD: 424.27±342.62 mg) were assessed 19.12±13.11 months following the DaTSCAN. In a multivariable linear regression analysis, when adjusted for DD and HY, z-caudate (B=-134.073, 95% CI -262.715 - -5.431, p=0.042) and z-striatum (B=-162.137, 95% CI -306.306 - -17.967, p=0.028), were statistically significant predictors of LEDD, while z-putamen was not (p=0.086).

DaT-uptake z-scores for caudate and striatum may serve as biomarkers that could predict LEDD requirement and guide treatment decisions towards personalized care for PwP.

Authors/Disclosures
Katarina Rukavina (King's College London)
PRESENTER
The institution of Ms. Rukavina has received research support from NIHR BRC. The institution of Ms. Rukavina has received research support from Parkinson's UK. Ms. Rukavina has received personal compensation in the range of $0-$499 for serving as a Speaker or Writer with Valid Insight, Profile Pharma and Britannia. .
Nicola Mulholland Nicola Mulholland has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AAA. Nicola Mulholland has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sirtex.
Ben Corcoran Ben Corcoran has nothing to disclose.
Juliet Staunton (King's College Hospital) Ms. Staunton has nothing to disclose.
Magdalena Krbot Skoric Magdalena Krbot Skoric has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
SIlvia Rota, MD Dr. Rota has nothing to disclose.
Alexandra Rizos, Other (King's College Hospital) An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GKC. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bial. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cynapsus. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lobsor. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stada. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zambon. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Profile Pharma. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Synovion. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scion. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Britannia. Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zambon. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. An immediate family member of Mrs. Rizos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim. An immediate family member of Mrs. Rizos has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Nature Parkinson's Journal. The institution of an immediate family member of Mrs. Rizos has received research support from EU. The institution of an immediate family member of Mrs. Rizos has received research support from Parkinson's UK. The institution of an immediate family member of Mrs. Rizos has received research support from Parkinson's Foundation. The institution of an immediate family member of Mrs. Rizos has received research support from Wellcome trust. The institution of an immediate family member of Mrs. Rizos has received research support from MRC. An immediate family member of Mrs. Rizos has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Mrs. Rizos has received publishing royalties from a publication relating to health care. An immediate family member of Mrs. Rizos has received publishing royalties from a publication relating to health care.
K *Use 019583 Ray Chaudhuri, MD,Other (King's College Hospital, London, UK) Prof. Ray Chaudhuri has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advisory board recent: AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Therevance, Scion, Britannia, Acadia, 4D Pharma. Prof. Ray Chaudhuri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial, Kyowa Kirin, SK Pharma . Prof. Ray Chaudhuri has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for GMC. The institution of Prof. Ray Chaudhuri has received research support from EU Horizon 2020, Parkinson's UK, NIHR, Parkinson's Foundation, Wellcome Trust Aacdemic grants over 2 years ago: Kirby Laing Foundation, MRC. Prof. Ray Chaudhuri has received publishing royalties from a publication relating to health care.